Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionEvaluation of Adverse Drug Properties with Cryopreserved Human Hepatocytes and the Integrated Discrete Multiple Organ Co-culture (IdMOC(TM)) SystemOATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesRole of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitorsInhibition of OATP-1B1 and OATP-1B3 by tyrosine kinase inhibitorsThe blood-testis barrier and its implications for male contraceptionThe SLCO (former SLC21) superfamily of transporters.Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.Drug transporters, the blood-testis barrier, and spermatogenesisInteraction of innovative small molecule drugs used for cancer therapy with drug transporters.Apple juice greatly reduces systemic exposure to atenololRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Assessment of gadoxetate DCE-MRI as a biomarker of hepatobiliary transporter inhibitionGenetic variations of bile salt transporters as predisposing factors for drug-induced cholestasis, intrahepatic cholestasis of pregnancy and therapeutic response of viral hepatitis.Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions.Pharmacogenetics of drug transporters in the enterohepatic circulation.Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response.Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 - 2013).Transporter-mediated drug-drug interactions with oral antidiabetic drugs.Biomarkers and human hepatocytes.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.Fentanyl pharmacokinetics is not dependent on hepatic uptake by organic anion-transporting polypeptide 1B1 in human beings.Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells.Characterization of ursodeoxycholic and norursodeoxycholic acid as substrates of the hepatic uptake transporters OATP1B1, OATP1B3, OATP2B1 and NTCP.Antitubercular Agent Delamanid and Metabolites as Substrates and Inhibitors of ABC and Solute Carrier Transporters.The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members.In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.Frequency of the SLCO1B1 388A>G and the 521T>C polymorphism in Tanzania genotyped by a new LightCycler®-based method.Glucuronidation: driving factors and their impact on glucuronide dispositionTransporters in Drug Discovery
P2860
Q24273350-4D8602EA-EDCE-4878-9F25-00DBF9452D33Q26801904-76DC0CA8-E604-44B6-9900-5D443FD3DBD8Q27001267-1562783C-76E2-4EF5-BBB3-78FC323DCAB2Q28236180-0E895F28-19E3-44AF-8653-9D850BE61E87Q28239708-E93B26A4-7FA3-49A2-8E0F-FD1D89722DC3Q28395237-935621CD-DACF-426C-ADA0-C19F9EE3599AQ34333710-BB2CCB61-B0C7-4133-9842-90083E0294C7Q35088420-32696725-B5B3-42D9-9661-E7276BCF93EAQ35240133-54D2D3EA-7769-4250-84DD-8A462482C295Q35708124-DD706344-BC3A-4918-888D-60E9B2DF5FB0Q36562479-15CFD973-733D-4786-B47E-0EB76849336DQ37121662-E6D5D960-86B1-4BC7-906D-C46165DB8DAAQ37279800-A6A1D0C2-8275-4AC1-B245-A214A6658A7AQ37841614-F47A2103-AB3C-4E0E-A6FF-BE9C730F7A0CQ37862576-F89A9545-C450-46A8-A6A0-3C2CD49FC1AFQ37880875-2E1FFE98-C4F6-40E1-9ACA-0BB2111D3D4DQ37964754-D7646CCE-81F1-4B5E-A545-17CCA8637281Q38075057-FF287879-D328-4974-93A5-E71E6B94394EQ38164084-02D47CBC-129B-4959-A81F-9FAC3986EF13Q38168993-3C688968-EE90-4CB3-88AE-DB9BFCA12B77Q38187449-FE2AB3A2-5635-4D05-96E1-BBCD8FA1F507Q38192698-90CA5532-1A4E-43D5-B39F-EAD1A9D84FC9Q38233298-226E4E34-0841-4C6F-B879-4B7B85C6351FQ39182431-81E4B293-0800-41E4-8DB8-1519AA4CF74BQ39359313-3057F5D3-930C-4DB9-8EFC-C56E8C3DA11EQ39472771-ED4061F4-50A5-4C96-BF9E-7D59A9CB169EQ39652527-E980184D-7E2A-4BC3-8630-E353DB8C2A72Q39883877-9EB7B0BA-8CC7-41F1-8FEF-728DBD8CEB46Q42714483-AC9CBCD6-1EC8-4D3A-A4CE-4E3258B9F9C9Q43638470-97810A4E-089F-4807-8C37-BEEB2C9E9F75Q43940364-22D05EE3-CCAB-4808-B7A1-414604BA97DEQ56030213-BF3E95A1-8316-43C5-960D-125AE3F1D6E3Q57684264-86410883-47B7-43AD-8F4C-286092C6926E
P2860
Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@en
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@nl
type
label
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@en
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@nl
prefLabel
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@en
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@nl
P2093
P2860
P1476
Hepatic OATP and OCT uptake tr ...... s and pharmacogenetic aspects.
@en
P2093
Christina Fahrmayr
Jörg König
Martin F Fromm
P2860
P304
P356
10.3109/03602530903491683
P407
P577
2010-08-01T00:00:00Z